TipRanks
Protagonist Therapeutics (DE:PGF)
BERLIN:PGF
Germany Market
PGF
Protagonist Therapeutics
RESEARCH TOOLSreports

Protagonist Therapeutics (PGF) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

PGF Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Protagonist
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PGF Stock 12 Month Forecast

Average Price Target

€145.72
▲(94.29% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is €145.72 with a high forecast of €162.30 and a low forecast of €105.58. The average price target represents a 94.29% change from the last price of €75.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"49":"€49","106":"€106","163":"€163","77.5":"€77.5","134.5":"€134.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":162.29799954,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€162.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.71917163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€145.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.58095669,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€105.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[49,77.5,106,134.5,163],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,81.71523073384616,88.43046146769231,95.14569220153847,101.86092293538462,108.57615366923076,115.29138440307693,122.00661513692307,128.72184587076924,135.43707660461538,142.15230733846153,148.8675380723077,155.58276880615387,{"y":162.29799954,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,80.43993627923076,85.87987255846154,91.3198088376923,96.75974511692309,102.19968139615385,107.63961767538461,113.07955395461539,118.51949023384616,123.95942651307692,129.3993627923077,134.83929907153845,140.27923535076923,{"y":145.71917163,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,77.35238128384616,79.70476256769231,82.05714385153846,84.40952513538461,86.76190641923077,89.11428770307693,91.46666898692308,93.81905027076922,96.17143155461538,98.52381283846154,100.87619412230768,103.22857540615385,{"y":105.58095669,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€162.30Average Price Target€145.72Lowest Price Target€105.58
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:PGF
Geoff Meacham
Citi
Citi
€152.7→€158.81
Buy
111.74%
Upside
Reiterated
09/09/26
Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
Truist Financial Analyst forecast on DE:PGF
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Teladoc (NYSE: TDOC) and Protagonist Therapeutics (NASDAQ: PTGX)
H.C. Wainwright Analyst forecast on DE:PGF
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€145.72→€148.34
Buy
97.78%
Upside
Assigned
09/01/26
Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright
Barclays Analyst forecast on DE:PGF
Etzer Darout
Barclays
Barclays
€133.5→€157.06
Buy
109.42%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)
Citizens JMP Analyst forecast on DE:PGF
Jonathan Wolleben
Citizens JMP
Citizens JMP
€143.97→€148.34
Buy
97.78%
Upside
Reiterated
08/31/26
Protagonist Therapeutics price target raised to $170 from $165 at CitizensProtagonist Therapeutics price target raised to $170 from $165 at Citizens
J.P. Morgan Analyst forecast on DE:PGF
Brian Cheng
J.P. Morgan
J.P. Morgan
€130.01
Buy
73.35%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Protagonist Therapeutics (PTGX), PMV Pharmaceuticals (PMVP)
Clear Street Analyst forecast on DE:PGF
Kaveri Pohlman
Clear Street
Clear Street
€150.95
Buy
101.27%
Upside
Reiterated
08/31/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
Goldman Sachs Analyst forecast on DE:PGF
Richard Law CFA
Goldman Sachs
Goldman Sachs
€162.3
Buy
116.40%
Upside
Reiterated
08/31/26
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
Wedbush Analyst forecast on DE:PGF
Yun Zhong
Wedbush
Wedbush
€150.95
Buy
101.27%
Upside
Reiterated
08/31/26
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
BMO Capital Analyst forecast on DE:PGF
Evan Seigerman
BMO Capital
BMO Capital
€155.32
Buy
107.09%
Upside
Reiterated
08/30/26
Analysts Conflicted on These Healthcare Names: Phio Pharmaceuticals (NASDAQ: PHIO), Ionis Pharmaceuticals (NASDAQ: IONS) and Protagonist Therapeutics (NASDAQ: PTGX)
TD Cowen Analyst forecast on DE:PGF
Tara Bancroft
TD Cowen
TD Cowen
€135.25
Buy
80.33%
Upside
Reiterated
08/05/26
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
Jefferies Analyst forecast on DE:PGF
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€105.58
Buy
40.77%
Upside
Reiterated
07/16/26
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
Leerink Partners Analyst forecast on DE:PGF
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€93.36→€95.98
Buy
27.98%
Upside
Reiterated
03/19/26
Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink
BTIG Analyst forecast on DE:PGF
Julian Harrison
BTIG
BTIG
€71.55
Buy
-4.60%
Downside
Reiterated
11/03/25
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:PGF
Geoff Meacham
Citi
Citi
€152.7→€158.81
Buy
111.74%
Upside
Reiterated
09/09/26
Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
Truist Financial Analyst forecast on DE:PGF
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Teladoc (NYSE: TDOC) and Protagonist Therapeutics (NASDAQ: PTGX)
H.C. Wainwright Analyst forecast on DE:PGF
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€145.72→€148.34
Buy
97.78%
Upside
Assigned
09/01/26
Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright
Barclays Analyst forecast on DE:PGF
Etzer Darout
Barclays
Barclays
€133.5→€157.06
Buy
109.42%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)
Citizens JMP Analyst forecast on DE:PGF
Jonathan Wolleben
Citizens JMP
Citizens JMP
€143.97→€148.34
Buy
97.78%
Upside
Reiterated
08/31/26
Protagonist Therapeutics price target raised to $170 from $165 at CitizensProtagonist Therapeutics price target raised to $170 from $165 at Citizens
J.P. Morgan Analyst forecast on DE:PGF
Brian Cheng
J.P. Morgan
J.P. Morgan
€130.01
Buy
73.35%
Upside
Reiterated
08/31/26
Analysts' Top Healthcare Picks: Protagonist Therapeutics (PTGX), PMV Pharmaceuticals (PMVP)
Clear Street Analyst forecast on DE:PGF
Kaveri Pohlman
Clear Street
Clear Street
€150.95
Buy
101.27%
Upside
Reiterated
08/31/26
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
Goldman Sachs Analyst forecast on DE:PGF
Richard Law CFA
Goldman Sachs
Goldman Sachs
€162.3
Buy
116.40%
Upside
Reiterated
08/31/26
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
Wedbush Analyst forecast on DE:PGF
Yun Zhong
Wedbush
Wedbush
€150.95
Buy
101.27%
Upside
Reiterated
08/31/26
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
BMO Capital Analyst forecast on DE:PGF
Evan Seigerman
BMO Capital
BMO Capital
€155.32
Buy
107.09%
Upside
Reiterated
08/30/26
Analysts Conflicted on These Healthcare Names: Phio Pharmaceuticals (NASDAQ: PHIO), Ionis Pharmaceuticals (NASDAQ: IONS) and Protagonist Therapeutics (NASDAQ: PTGX)
TD Cowen Analyst forecast on DE:PGF
Tara Bancroft
TD Cowen
TD Cowen
€135.25
Buy
80.33%
Upside
Reiterated
08/05/26
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
Jefferies Analyst forecast on DE:PGF
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€105.58
Buy
40.77%
Upside
Reiterated
07/16/26
Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
Leerink Partners Analyst forecast on DE:PGF
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€93.36→€95.98
Buy
27.98%
Upside
Reiterated
03/19/26
Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink
BTIG Analyst forecast on DE:PGF
Julian Harrison
BTIG
BTIG
€71.55
Buy
-4.60%
Downside
Reiterated
11/03/25
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
LFMDLifeMD
ORKAOruka Therapeutics
ACHVAchieve Life Sciences
PLSEPulse Biosciences
PMNProMIS Neurosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

3 Months
Tara BancroftTD Cowen
Success Rate
11/13 ratings generated profit
85%
Average Return
+11.78%
Copying Tara Bancroft's trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +11.78% per trade.
1 Year
Tara BancroftTD Cowen
Success Rate
13/13 ratings generated profit
100%
Average Return
+74.07%
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.07% per trade.
2 Years
Tara BancroftTD Cowen
Success Rate
13/13 ratings generated profit
100%
Average Return
+126.68%
Copying Tara Bancroft's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +126.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PGF Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
26
14
16
24
27
Hold
2
2
2
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
16
18
25
27
In the current month, PGF has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PGF average Analyst price target in the past 3 months is 145.72.
Each month's total comprises the sum of three months' worth of ratings.

PGF Financial Forecast

PGF Earnings Forecast

Next quarter’s earnings estimate for PGF is €2.12 with a range of €0.11 to €3.24. The previous quarter’s EPS was €2.00. PGF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.
Next quarter’s earnings estimate for PGF is €2.12 with a range of €0.11 to €3.24. The previous quarter’s EPS was €2.00. PGF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.

PGF Sales Forecast

Next quarter’s sales forecast for PGF is €209.92M with a range of €83.05M to €255.27M. The previous quarter’s sales results were €186.62M. PGF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.
Next quarter’s sales forecast for PGF is €209.92M with a range of €83.05M to €255.27M. The previous quarter’s sales results were €186.62M. PGF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PGF has Performed in-line its overall industry.

PGF Stock Forecast FAQ

What is DE:PGF’s average 12-month price target, according to analysts?
Based on analyst ratings, Protagonist Therapeutics’s 12-month average price target is 145.72.
    What is DE:PGF’s upside potential, based on the analysts’ average price target?
    Protagonist Therapeutics has 94.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Protagonist Therapeutics a Buy, Sell or Hold?
          Protagonist Therapeutics has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Protagonist Therapeutics’s share price target?
            The average share price target for Protagonist Therapeutics is 145.72. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €162.30 ,and the lowest forecast is €105.58. The average share price target represents 94.29% Increase from the current price of €75.
              What do analysts say about Protagonist Therapeutics?
              Protagonist Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Protagonist Therapeutics?
                To buy shares of DE:PGF, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.